Page 72 - 2019_02-Haematologica-web

J.H. Yoon et al.
7. Takahashi N, Chubachi A, Kume M, et al. A
clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. Int J Hematol. 2001;74(2):209-213.
8. Li J, Wang Q, Zheng W, et al. Hemophagocytic lymphohistiocytosis: clini- cal analysis of 103 adult patients. Medicine. 2014;93(2):100-105.
9. Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohisti- ocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol. 2011;33(1):35-39.
10. Imashuku S, Tabata Y, Teramura T, Hibi S. Treatment strategies for Epstein-Barr virus- associated hemophagocytic lymphohistio- cytosis (EBV-HLH). Leuk Lymphoma. 2000;39(1-2):37-49.
11. Kaito K, Kobayashi M, Katayama T, et al. Prognostic factors of hemophagocytic syn- drome in adults: analysis of 34 cases. Eur J Haematol. 1997;59(4):247-253.
12. Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lympho- proliferative disease using B-cell-directed therapy. Blood. 2005;105(3):994-996.
13. Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refracto- ry hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81(1):59-61.
14. Olin RL, Nichols KE, Naghashpour M, et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemo- phagocytic lymphohistiocytosis. Am J Hematol. 2008;83(9):747-749.
15. Shiraishi A, Ohga S, Doi T, et al. Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associ- ated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2012;59(2):265-270.
16. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophago- cytic lymphohistiocytosis with alemtuzum- ab. Pediatr Blood Cancer. 2013;60(1):101- 109.
17. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunothera- peutic regimens. Br J Haematol. 2013;162 (3):376-382.
18. Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a sal- vage therapy for adult refractory hemo- phagocytic lymphohistiocytosis. Blood. 2015;126(19):2186-2192.
19. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lympho- histiocytosis with HLH-94 immuno- chemotherapy and bone marrow transplan- tation. Blood. 2002;100(7):2367-2373.
20. Cooper N, Rao K, Gilmour K, et al. Stem cell transplantation with reduced-intensity con- ditioning for hemophagocytic lymphohisti- ocytosis. Blood. 2006;107(3):1233-1236.
transplant lymphoproliferative disorder.
Clin Transplant. 1995;9(1):53-59.
30. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunc- tion with immunosuppressive chemothera- py as a novel therapy for Epstein Barr virus- associated hemophagocytic lymphohistio- cytosis. J Pediatr Hematol Oncol.
2007;29(8):569-573.
31. Strout MP, Seropian S, Berliner N.
Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistio- cytosis. Nat Rev Clin Oncol. 2010;7(7):415-
21. Machaczka M, Nahi H, Karbach H, Klimkowska M, Hagglund H. Successful
treatment of recurrent malignancy-associat-
ed hemophagocytic lymphohistiocytosis
with a modified HLH-94 immuno- 420.
chemotherapy and allogeneic stem cell transplantation. Med Oncol. 2012;29(2): 1231-1236.
22. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohisti- ocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991;18(1): 29-33.
23. ParkKH,ParkH,KimM,KimY,HanK,Oh EJ. Evaluation of NK cell function by flowcy- tometric measurement and impedance based assay using real-time cell electronic sensing system. Biomed Res Int. 2013;2013:210726.
24. Henter JI, Arico M, Egeler RM, et al. HLH- 94: a treatment protocol for hemophagocyt- ic lymphohistiocytosis. HLH study group of the Histiocyte Society. Med Pediatr Oncol. 1997;28(5):342-347.
25. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and out- comes of adults with hemophagocytic lym- phohistiocytosis. Mayo Clin Proc. 2014;89 (4):484-492.
26. Imashuku S, Hibi S, Kuriyama K, et al. Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2000;36(3-4):339-346.
27. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemo- phagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood. 1999;93(6):1869-1874.
32. Gratama JW, Oosterveer MA, Zwaan FE, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone mar- row transplantation: implications for sites of viral latency. Proc Natl Acad Sci USA. 1988;85(22):8693-8696.
33. Ohga S, Kudo K, Ishii E, et al. Hematopoietic stem cell transplantation for familial hemo- phagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophago- cytic lymphohistiocytosis in Japan. Pediatr Blood Cancer. 2010;54(2):299-306.
34. Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118(22):5794-5798.
35. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052.
36. Zhang K, Chandrakasan S, Chapman H, et al. Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocyto- sis. Blood. 2014;124(8):1331-1334.
37. Filipovich AH. Hemophagocytic lymphohis- tiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009;127-131.
38. Gupta A, Tyrrell P, Valani R, Benseler S, Weitzman S, Abdelhaleem M. The role of the initial bone marrow aspirate in the diag- nosis of hemophagocytic lymphohistiocyto- sis. Pediatr Blood Cancer. 2008;51(3):402-
28. Sullivan JL, Woda BA, Herrod HG, Koh G, 404.
Rivara FP, Mulder C. Epstein-Barr virus-asso- ciated hemophagocytic syndrome: virologi- cal and immunopathological studies. Blood. 1985;65(5):1097-1104.
29. Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL. Antiviral prophylax- is and the Epstein Barr virus-related post-
39. Strauss R, Neureiter D, Westenburger B, Wehler M, Kirchner T, Hahn EG. Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocy- tosis in critically ill medical patients--a post- mortem clinicopathologic analysis. Crit Care Med. 2004;32(6):1316-1321.
276
haematologica | 2019; 104(2)